Abstract
Orally inhaled and nasal drug products (OINDP) are regulated in Europe via national (country) legislation and guidelines and/or legislation established in the European Union and resulting guidelines developed by the European Medicines Agency (EMA). Recent movement in EMA guidance and European Commission legislation implies potential significant changes in OINDP regulation. The UK exiting the European Union (“Brexit”) has also raised a number of questions related to OINDP development and regulation in the region. The International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) European outreach working group provides and overview and analysis of the current state of European regulatory activity for OINDP (International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) 2018).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lim J. Review impact of emerging EMA/MHRA guidelines and standards. 2016. http://ipacrs.org/news-events/events/2016ipacrssymposium Accessed 22 May 2018.
For information on the International Pharmaceutical Aerosol Consortium on Regulation and Science, its mission and activities, see https://ipacrs.org/.
European Parliament, European Council. In: Official Journal of the European Union. Regulation (EU) 2017/745 of the European Parliament and of The Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. 2017. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2017.117.01.0001.01.ENG&toc=OJ:L:2017:117:TOC Accessed 22 May 2018.
European Parliament, European Council. In: Official Journal of the European Union. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. 2001. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32001L0083&qid=1495222998822 Accessed 22 May 2018.
European Medicines Agency. Guideline on pharmaceutical quality of inhalation and nasal products. 2006. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000805.jsp&mid=WC0b01ac0580028eb3 Accessed 22 May 2018.
European Medicines Agency. Guideline on requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for the treatment of asthma in children and adolescents. 2009. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001151.jsp&mid=WC0b01ac0580034cf6 Accessed 22 May 2018.
European Medicines Agency. Quality of medicines questions and answers, part 2. Specific types of product – orally inhaled products (published 6 March 2017) http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000072.jsp#section11 Accessed 22 May 2018.
European Medicines Agency. Clinical investigation of medicinal products for the treatment of asthma. 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001146.jsp&mid=WC0b01ac0580034cf6 Accessed 22 May 2018.
European Medicines Agency. Concept Paper on development of a guideline on quality requirements of medicinal products containing a device component for delivery or use of the medicinal product (EMA/CHMP/QWP/BWP/661488/2016). http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001812.jsp&mid. Accessed on 22 May 2018.
European Medicines Agency. Concept Paper on revision of Guideline on Pharmaceutical Quality of Inhalation and Nasal Drug Products. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000805.jsp&mid=WC0b01ac0580028eb3. Accessed 22 May 2018.
European Medicines Agency. Concept paper on revision of the guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for the treatment of asthma in children and adolescents. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/03/WC500224137.pdf. Accessed 4 February 2018.
European Medicines Agency. Clinical development of medicinal products for the treatment of cystic fibrosis. 2009. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/clinical_respiratory_system/general_content_001148.jsp&mid=WC0b01ac0580034cf6. Accessed 22 May 2018.
European Commission. Press release. New EU rules on medical devices to enhance patient safety and modernise public health. Greater than 500,000 types of medical devices and in-vitro diagnostic medical devices on the EU market. Brussels, 5 April 2017.
New EU regulations to ensure medical device safety in Q&A format - European Commission - Fact Sheet: New EU rules to ensure safety of medical devices- Brussels, 5 April 2017.
EUDAMED: European Database on Medical Devices. http://ec.europa.eu/idabc/en/document/2256/5637.html. Accessed 31 July 2018.
European Commission outlined new legislation in summary provided via press release -New EU rules on medical devices to enhance patient safety and modernise public health - Brussels, 5 April 2017.
European Medicines Agency. Generic and Hybrid Medicines. The EMA defines hybrid medicines as “medicines whose authorisation depends partly on the results of tests on the reference medicine and partly on new data from clinical trials. This happens when a manufacturer develops a generic medicine that is based on a reference medicine, but has a different strength, a different route of administration or a slightly different indication from the reference medicine.” http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000335.jsp&mid=WC0b01ac0580514d5c Accessed on 22 June 2018.
Medicines and Healthcare Products Regulatory Agency. MHRA delivers guidance on human factors. https://www.gov.uk/government/news/mhra-delivers-guidance-on-human-factors. September 2017. Accessed 4 Feb 2018.
Medicines and Healthcare Products Regulatory Agency. Guidance. Medical devices: EU regulations for MDR and IVDR. https://www.gov.uk/guidance/medical-devices-eu-regulations-for-mdr-and-ivdr Accessed 4 Jan 2018.
European Council. European Medicines Agency to be relocated to Amsterdam, the Netherlands. http://www.consilium.europa.eu/en/press/press-releases/2017/11/20/european-medicines-agency-to-be-relocated-to-city-country/. Accessed 3 Jan 2018.
Medicines and Healthcare Products Regulatory Agency. MHRA and making a success of Brexit. https://www.gov.uk/government/news/medicines-and-healthcare-products-regulatory-agency-statement-on-the-outcome-of-the-eu-referendum. Accessed 22 May 2018.
Barber S. Briefing Paper: Brexit and medicines regulation. House of Commons Library. Number 8148. 20 November 2017. http://researchbriefings.parliament.uk/ResearchBriefing/Summary/CBP-8148 Accessed 3 Jan 2018.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Articles and procedures. http://www.ich.org/about/articles-procedures.html. Accessed 4 Jan 2018.
Medicines and Healthcare Products Regulatory Agency. MHRA update to pharmaceutical companies on exit preparations. An update from the Medicines and Healthcare products Regulatory Agency (MHRA) to pharmaceutical companies on preparations for exiting the European Union. 16 January 2018. https://www.gov.uk/government/news/mhra-update-to-pharmaceutical-companies-on-exit-preparations. Accessed 6 February 2018.
European Federation of Pharmaceutical Industries and Associations. United Kingdom exit from the European Union “Brexit.” Life Science Industry Coalition position paper. https://www.efpia.eu/news-events/the-efpia-view/blog-articles/brexit/ Accessed 7 Feb 2018.
European Commission. Questions and Answers related to the United Kingdom’s withdrawal from the European Union with regard to the medicinal products for human and veterinary use within the framework of the Centralised Procedure. 29 January 2018. http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_001891.jsp&mid=WC0b01ac0580cb2e5b Accessed 22 May 2018.
International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS). https://ipacrs.org/. Accessed 22 May 2018.
Author information
Authors and Affiliations
Corresponding author
Additional information
Recent activity in EMA guidance and European Commission legislation implies potential significant changes in orally inhaled and nasal drug products (OINDP) regulation. The International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) European outreach working group provides an overview and analysis.
Rights and permissions
About this article
Cite this article
Santos, C., Marco, G., Nagao, L.M. et al. European Regulatory Developments for Orally Inhaled and Nasal Drug Products. AAPS PharmSciTech 19, 3134–3140 (2018). https://doi.org/10.1208/s12249-018-1154-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-018-1154-5